SynthesisFrontiers in pharmacology2025
Efficacy and safety of
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- G Protein-Coupled Receptor in High-Altitude Diseases: Mechanistic Insights and Therapeutic Opportunities.MedComm · 2026Review
- Xinnaoxin tablets ameliorate high-altitude polycythemia-associated cardiac injury by regulating the NF-κB, MAPK, and PI3K/AKT signaling pathways.Frontiers in pharmacology · 2026Article
- Acute high-altitude illness: risk factors, susceptibility prediction, and personalized prevention and treatment.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To evaluate the efficacy and safety of Methods: This study systematically retrieved randomized controlled trials (RCTs) published prior to September 2024 from eight distinct databases. It included AHAD patients, with the control group receiving either conventional western medicine (WM) or placebo, and the experimental group receiving RCE alone or in conjunction with WM. The primary outcomes were arterial oxygen saturation (SaO Results: This study included 19 eligible RCTs with 1,690 participants. In improving SaO Conclusion: RCE may enhance blood oxygen levels and mitigate clinical symptoms in the treatment of AHAD with favorable safety. Nonetheless, it is imperative to undertake further rigorous RCTs to validate these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier CRD42024593081.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.